Fosun Pharma Signs an Agreement with BioNTech to Develop and Commercialize BNT162 for COVID-19

 Fosun Pharma Signs an Agreement with BioNTech to Develop and Commercialize BNT162 for COVID-19

Fosun Pharma Signs an Agreement with BioNTech to Develop and Commercialize BNT162 for COVID-19

Shots:

  • BioNTech to receive $135M as up front, future investment & milestone payments and $50M as an equity investment for 1,580,777 ordinary shares in BioNTech. Fosun to get the rights to commercialize BNT162 in China while BioNTech retain all rights of the vaccine in ROW
  • The companies will jointly conduct clinical studies of BNT162 in China, leveraging BioNTech’s mRNA vaccine technology and Fosun’s clinical development and commercialization capabilities in China
  • The companies will share profits from sales in China. Additionally, BioNtech with its partner Polymun will supply the mRNA vaccine for clinical studies from GMP manufacturing facilities in the EU

Click here ­to­ read full press release/ article | Ref: Business wire | Image: Businesswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post